Inogen Releases Enhanced Inogen One G3 Oxygen Concentrator

GOLETA, Calif., Dec. 8, 2015 (GLOBE NEWSWIRE) -- Inogen, Inc. (INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has released to market an enhanced Inogen One G3 portable oxygen concentrator.

The Inogen One G3 portable oxygen concentrator has been expanded from four flow settings to five, and total oxygen production has been increased by 25% with no added size or weight. The product offers the highest oxygen output of any portable oxygen concentrator of the same weight. In addition to increased oxygen production, the sound level of the Inogen One G3 has been lowered from approximately 42 decibels to 39 decibels. The upgraded product will first be available to customers in the Company's domestic direct-to-consumer channel followed by a phased roll out to the Company's other sales channels around the world.

"Ongoing product innovation is a key objective for us. We are excited to introduce improvements to our Inogen One G3 that include 25% additional oxygen production at the same size and weight, with reduced sound levels," said Raymond Huggenberger, Inogen President and CEO. "Our patients and business partners alike have been pleased with the performance of the Inogen One G3 since it was first released in 2012 and we are excited to launch improvements to the product that keep it and Inogen at the forefront of innovation."

Inogen has used, and intends to continue to use, its Investor Relations website,, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit

Use of Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements concerning the performance of our Inogen One G3 portable oxygen concentrator, future financial performance or trends, and growth opportunities affecting Inogen. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to, risks arising from the possibility that Inogen will not realize anticipated revenue; the impact of reduced reimbursement rates, including in connection with the implementation of the competitive bidding and the Center for Medicare and Medicaid Services (CMS) rules; the possible loss of key employees, customers, or suppliers; and intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products. In addition, Inogen's business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; its ability to successfully launch new products and applications; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen's business and operating results are contained in Inogen's Annual Report on Form 10-K for the year ended December 31, 2014 and in Inogen's subsequent reports filed with the Securities and Exchange Commission, including Inogen's Quarterly Report on Form 10-Q for the period ended September 30, 2015. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.

About Inogen

Inogen is innovation in oxygen therapy. We are a medical technology company that develops, manufactures and markets innovative oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit

Investor Relations Contact:
805-562-0500 ext 7
Media Contact:
Byron Myers

Back to news